thiethylperazine malate - Profile

What are the generic drug sources for thiethylperazine malate and what is the scope of patent protection?

Thiethylperazine malate is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for thiethylperazine malate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for thiethylperazine malate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TORECAN	thiethylperazine malate	INJECTABLE;INJECTION	012754-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Thiethylperazine Malate Investment Scenario and Patent-Led Fundamentals Analysis: Exclusivity, Competitive Risk, and Licensing/Regulatory Pathways

Last updated: June 26, 2026

Thiethylperazine malate is an older, small-molecule phenothiazine-class antiemetic/antihistamine. For an investment-grade IP and exclusivity-led view, the case hinges on whether any currently marketed thiethylperazine malate product is covered by unexpired formulation, process, or method-of-use patents in the target geographies. Without confirmed active patents on thiethylperazine malate products, near-term economics skew toward generic-driven price compression and limited differentiated upside.

What patents protect thiethylperazine malate (API, salts, formulations, and uses)?

Direct answer: Patent protection for thiethylperazine malate typically clusters around (1) salt-form composition claims, (2) specific solid-state/formulation compositions, (3) manufacturing/process claims, and (4) method-of-use claims for antiemetic indications. Investment relevance depends on which of these are still in force for the exact marketed dosage forms (tablets vs drops vs other presentations) and which jurisdictions have active listings.

How does “thiethylperazine” patent coverage usually map in practice?

For legacy antiemetics, modern patent estates are often narrower and tied to:

• Specific dosage forms (immediate-release tablets, liquid formulations)
• Stabilized or improved formulation compositions
• Manufacturing steps that reduce impurity profiles
• Narrower method-of-use claims (e.g., refractory nausea, specific clinical contexts)

Which claim types are most likely to matter for licensing and litigation?

• Formulation and process patents: more likely to survive as “entry barriers” for generics when they remain unexpired.
• Method-of-use patents: can be strong if they align with how the sponsor markets.
• Salt-form patents: can block entry if the exact salt is claimed and the generic uses a different salt or a non-infringing process.

Investment implication of older small-molecule estates

In legacy small-molecule antiemetics, the economic center of gravity usually shifts from exclusivity to:

• Channel access and procurement contracts
• Distribution footprint (hospital and retail)
• Product line extensions (pediatric dosing forms, combination products)
• Regulatory strategy for generic approvals

When does thiethylperazine malate lose exclusivity (patent expiry vs regulatory exclusivity)?

Direct answer: Exclusivity for thiethylperazine malate will typically be driven by the expiry of the last unexpired patent covering the specific marketed product (formulation/process/use) rather than by biologics-style market exclusivity. If no unexpired patents cover current dosage forms in major markets, the investment timeline compresses toward generic availability.

What are the exclusivity mechanisms investors should look for?

For small molecules, exclusivity commonly includes:

• Granted patents expiring by date (composition/formulation/process/use)
• Regulatory data exclusivity windows (varies by jurisdiction and approval history)
• Orphan exclusivity (if applicable, which is unlikely for a legacy antiemetic unless a distinct orphan indication exists)

Timeline logic used in investment models for legacy generics

Build a “last-to-expire” clock from:

• Core API/composition claims (often long expired)
• Salt/form claims (sometimes persist)
• Formulation/process patents (often last remaining)
• Any life-cycle method-of-use claims tied to labeling

What is the Orange Book status of thiethylperazine malate (US) and how does that affect generic entry risk?

Direct answer: An Orange Book listing drives US generic entry risk because Paragraph IV challenges and “carve-out” switching to non-listed strengths/forms depend on those listings. However, an investment-grade conclusion requires the specific US NDA/ANDA or listed product(s) and their listed patents.

Why Orange Book status is decisive for investment modeling

For thiethylperazine malate, the investment question is:

• Are there currently listed patents for a thiethylperazine malate product?
• Are those patents near expiry?
• Do they cover the exact strength and dosage form intended for commercialization?

Generic entry risk framework for small molecules

• If no active Orange Book patents cover the target product: immediate generic entry risk rises materially.
• If active patents exist: entry depends on Paragraph IV litigation and design-around feasibility (different salt, different formulation/process).

How many patents cover thiethylperazine malate and what is the likely “patent density” by jurisdiction?

Direct answer: Patent density is usually low-to-moderate for legacy antiemetics in major markets unless the sponsor pursued multiple life-cycle filings around formulation/process. For investors, the key is not the count but the remaining term and claim breadth relative to likely generic designs.

Practical “density” interpretation investors use

• Low density with long remaining term: fewer but broader claims.
• High density but many narrow claims: higher likelihood of design-around through formulation/process tweaks.
• Mixed estates across jurisdictions: litigation and settlement strategy become geography-specific.

What formulation patents protect thiethylperazine malate (tablets, liquids, stability, impurities)?

Direct answer: For thiethylperazine malate, formulation patent protection (if present) most often targets stability, impurity control, and manufacturability of a specific dosage form. These are the patents that most commonly remain relevant after core composition expiry.

Formulation categories that attract patenting

• Solid dosage forms: binder/filler systems, disintegration characteristics, coating compositions
• Liquid dosage forms: solvent system, pH adjustment strategy, antioxidant/preservative stabilization
• Impurity-control methods: defined impurities and process parameters

Investment impact

• If formulation patents remain unexpired and are hard to design around, generics face delayed entry or licensing.
• If formulation patents are expired or easy to circumvent, pricing pressure dominates.

What method-of-use patents exist for thiethylperazine malate (indications, dosing regimens, and clinical contexts)?

Direct answer: Method-of-use patents for older antiemetics can exist but are often narrow and tied to specific clinical contexts and dosing. Their investment value depends on alignment with current labeling and payer uptake.

Where method-of-use claims usually anchor

• Nausea and vomiting indications
• Specific refractory subsets (if claimed)
• Perioperative or chemotherapy contexts (if the label matches)

Investment relevance

Method-of-use patents matter if:

• They are still unexpired in key markets
• They map directly to the intended promotional claims and reimbursement environment

Which companies are challenging thiethylperazine malate and what Paragraph IV risks exist?

Direct answer: A Paragraph IV challenger list is only computable from confirmed US ANDA filings and Orange Book data for thiethylperazine malate products. Without a verified listing-to-patent mapping, a defensible competitive litigation risk statement cannot be produced.

What patent litigation affects thiethylperazine malate (settlements, injunctions, and timelines)?

Direct answer: Litigation outcomes drive generic entry timing and investor returns only when linked to specific patents, ANDA applicants, and district court outcomes. A complete timeline requires confirmed case dockets and patent numbers tied to thiethylperazine malate product listings.

How does thiethylperazine malate compare with competing antiemetics on IP defensibility?

Direct answer: As a phenothiazine antiemetic, thiethylperazine malate competes in a large generic market where most brands are older and patent estates often expired. IP defensibility typically comes from:

• Remaining formulation/process patents in targeted geographies
• Product differentiation through dosing form or stability improvements
• Supply-chain reliability and contract pricing rather than exclusivity

Competitive set investors usually model

• Other antiemetics and antihistamine phenothiazines in generic channels
• Newer classes (where patents are active) mainly by therapeutic substitution risk rather than direct IP competition

What is the FDA regulatory status of thiethylperazine malate and what does it imply for market entry?

Direct answer: FDA regulatory status must be tied to an exact product: NDA holder, dosage form, strength, and whether it is discontinued or active. Those details determine whether generic applicants can reference listed drugs and whether any exclusivity blocks them.

Investment implication of regulatory posture

• Active NDA with listed patents: entry risk is patent-dependent.
• Discontinued or unapproved status: entry depends on whether a “reference listed drug” is available and on regulatory pathway choices.
• Switch to different salt or dosage form: may allow easier design-around.

What generic entry risks exist for thiethylperazine malate (design-around: different salt, formulation, or process)?

Direct answer: Generic entry risk for thiethylperazine malate is primarily a function of:

• Whether any unexpired patents cover the exact salt form and dosage form
• Whether design-around is feasible by changing salt, excipient system, or process parameters
• Whether Orange Book listings create practical barriers in the US

Typical generic design-around strategies for legacy salt drugs

• Use a different counterion salt (if claims are salt-specific)
• Match API but alter formulation composition
• Use alternative manufacturing parameters to avoid process-claim infringement

Revenue exposure and commercial fundamentals: is thiethylperazine malate a high-upside or low-upside bet?

Direct answer: On fundamentals alone, thiethylperazine malate is structurally exposed to:

• Price compression from generic supply expansion
• Regulatory and payer behavior that prioritizes lowest acquisition cost
• Limited differentiation unless tied to a protected formulation/product line

What tends to drive profitability in this segment

• Contract manufacturing capacity and cost leadership
• Competitive procurement in hospitals
• Low marketing intensity relative to branded niche players (if any)
• Avoidance of lifecycle patent carve-outs unless protected by enforceable claims

Investment posture that matches these fundamentals

• Upside case: protectable product-specific formulation/process still unexpired in key markets plus evidence of sustained demand.
• Base case: generics dominate; returns hinge on supply economics and market access.
• Downside case: last patents expired or weak; entry accelerates; margin declines.

Key litigation and exclusivity “watchlist” investors track for thiethylperazine malate

Direct answer: The watchlist is the unexpired patent set tied to any active, marketed thiethylperazine malate products and their specific Orange Book listings (if US). Without verified patent-and-product linkage, no credible watchlist can be enumerated.

Key Takeaways

• Thiethylperazine malate investment outcomes are driven by product-specific unexpired patents, not by generic class characteristics.
• Exclusivity is likely to be limited to formulation/process/use claims with remaining term in specific jurisdictions, if any.
• US generic entry timing depends on Orange Book listings tied to the exact thiethylperazine malate dosage form and strength.
• If no active listed patents exist for the marketed product in key markets, returns skew toward low-single-digit upside with heavy reliance on supply economics and contracting.

FAQs

1. How do salt-form patents for thiethylperazine malate typically affect generic entry in the US?
2. What formulation attributes (stability, impurity profile, excipient system) most often define enforceable patents for oral thiethylperazine malate products?
3. What is the fastest US pathway for generic thiethylperazine malate if no active Orange Book patents remain?
4. How do method-of-use claims for nausea and vomiting alter labeling and promotional constraints for thiethylperazine malate sponsors?
5. Which market-access levers (tendering, hospital procurement, distribution) most influence profitability for older generic antiemetics like thiethylperazine malate?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. ANDA regulations and submission framework. U.S. Food and Drug Administration.